Back to top
more

Surmodics (SRDX)

(Real Time Quote from BATS)

$35.10 USD

35.10
123,752

+0.07 (0.20%)

Updated Aug 7, 2025 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PerkinElmer Launches Workstations for Coronavirus Testing

by Zacks Equity Research

PerkinElmer's (PKI) scalable and modular explorer automated workstations simplify testing workflows, thereby expediting the process of SARS-CoV-2 RT-PCR testing.

Zacks Equity Research

Masimo PVi Gets FDA Approval to Measure Fluid Responsiveness

by Zacks Equity Research

The FDA approval of Masimo's (MASI) PVi system will enable patient safety.

Zacks Equity Research

Surmodics (SRDX) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered revenue growth in each of its core units viz. In Vitro Diagnostics and Medical Device in Q3.

Zacks Equity Research

SurModics (SRDX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

SurModics (SRDX) delivered earnings and revenue surprises of 110.00% and 8.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Add AMN Healthcare to Your Portfolio

by Zacks Equity Research

Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.

Zacks Equity Research

Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis

by Zacks Equity Research

PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.

Zacks Equity Research

Masimo (MASI) Introduces Automation and Connectivity Solution

by Zacks Equity Research

Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.

Zacks Equity Research

Here's Why You Should Retain Merit Medical (MMSI) for Now

by Zacks Equity Research

Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.

Zacks Equity Research

VREX vs. SRDX: Which Stock Is the Better Value Option?

by Zacks Equity Research

VREX vs. SRDX: Which Stock Is the Better Value Option?

Zacks Equity Research

QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results

by Zacks Equity Research

Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.

Zacks Equity Research

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investor confidence is high on Nevro (NVRO), thanks to solid prospects

Zacks Equity Research

BD Unveils BD PurPrep Patient Preoperative Skin Preparation

by Zacks Equity Research

By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.

Zacks Equity Research

Here's Why You Should Retain Avanos Medical Stock for Now

by Zacks Equity Research

Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Retain DaVita in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on DaVita (DVA), thanks to solid prospects.

Zacks Equity Research

NextGen Virtual Visits Offers Remote Eye Care Facilities

by Zacks Equity Research

The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.

Zacks Equity Research

LHC Group Inks Deal With Orlando Health to Improve HCBS

by Zacks Equity Research

This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.

Zacks Equity Research

Quidel (QDEL) Catches Eye: Stock Jumps 6.3%

by Zacks Equity Research

Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Why Surmodics (SRDX) Could Be Positioned for a Surge

by Zacks Equity Research

Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Equity Research

Ecolab's Unit Unveils Test Kit for Cooling Water Management

by Zacks Equity Research

Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for June 29th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 29th.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for June 26th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 26th

Zacks Equity Research

Here's Why You Should Add Surmodics to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.

Zacks Equity Research

NextGen Virtual Visits Supports Women Health During COVID-19

by Zacks Equity Research

Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.